Microbiome

An average person contains 30 trillion human cells, but even more microbes – about 39 trillion. In addition, there are possibly ten times that number of viral particles in the human virome. Understanding an individual’s microbiome is becoming increasingly important for diagnosing a broad range of diseases.

Patents that relate to the microbiome often need to be drafted differently from patents covering small molecule drugs or conventional diagnostics. For instance, some inventions lie in a way of affecting or detecting a heterogenous population of microbial cells. The cells could be defined in various ways, such as by their function or by their degree of genetic relatedness to a reference organism. Other inventions lie in a way of assessing the impact of the heterogenous population of microbes on drug metabolism, which might require functional definitions and/or specific assays to be written into the claims.

Applicants for microbiome-based patents need to be aware of legal obstacles in certain jurisdictions that would make certain claims very difficult to obtain. At Mewburn Ellis LLP, our world class training and broad experience makes us an excellent choice to be your creative, trusted advisors in this rapidly developing space.

To find out more, view our spotlight page here.

Open pages of EPO Opposition Trends in the Life Sciences Sector

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

Enzyme engineering with AI – the latest chapter (in a long story…)

Enzyme engineering with AI – the latest chapter (in a long story…)

by Simon Kremer

For those of us who studied Biochemistry at college, the classic active site “catalytic triad” of serine peptidases was often our first introduction to the fascinating world of enzymes (and also, ...

HutanBio: algae is the fuel of the future

HutanBio: algae is the fuel of the future

by Simon Kremer

Algae converts sunlight and carbon dioxide into flammable hydrocarbons, offering a like-for-like replacement for fossil fuels.

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

by Adam Gregory

In vivo cell therapy is emerging as a groundbreaking approach to reduce the cost and expand the availability of cell therapies. Unlike traditional ex vivo approaches where cells are extracted, ...

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

by Helen Brew Gerlach

We are delighted to release our latest report Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know. View the report here.

Discontinuous Epitope Claims get Green Light in Europe

Discontinuous Epitope Claims get Green Light in Europe

by Edward Couchman

Patents for antibodies defined by discontinuous epitopes have garnered a lot of attention recently. Following the decision of the US Supreme Court in Amgen v Sanofi, it has now been the turn of the ...

Hummingbird Bioscience’s multi-payload ADC technology licensed by Callio Therapeutics

Hummingbird Bioscience’s multi-payload ADC technology licensed by Callio Therapeutics

by Adam Gregory

We are delighted to congratulate our client Hummingbird Bioscience on the successful out-licensing of multi-payload antibody-drug conjugate (ADC) technology and related intellectual property and ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.